Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

890

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer
Recurrent Fallopian Tube Cancer
Recurrent Primary Peritoneal Cancer
Recurrent Endometrial Cancer
Endometrial Cancer
Low-grade Serous Ovarian Cancer

Interventions

DRUG: Ubamatamab
DRUG: Cemiplimab
DRUG: Sarilumab
DRUG: Tocilizumab

Sponsor

Regeneron Pharmaceuticals